UNSPSC 51142543: Apomorphine hydrochloride

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula 2C17H17NO2.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F39049Y068, chemically known as 6a.beta.-noraporphine-10,11-diol, 6-methyl-, hydrochloride but more generally known as apomorphine hydrochloride, which bears US NIH Compound Identifier 2215. European Medicines Agency schedules Apomorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12924MIG.

UNSPSC 51142543 Apomorphine hydrochloride (Commodity) covers pharmaceutical products that state and local governments procure through health and human services programs, though the recent opportunities tagged to this code do not actually involve apomorphine but rather naloxone, generic multi-source pharmaceuticals, and over-the-counter products. State and local health departments, county public health agencies, and cooperative purchasing alliances are the primary issuing bodies. The scope of work encompasses direct procurement of individual pharmaceutical products from manufacturers and authorized distributors, with delivery to county health facilities, state health agencies, and participating local health systems. Contracts typically run two years with optional renewals, include quarterly or as-needed deliveries, and require vendors to maintain cGMP certification, comply with Drug Supply Chain Security Act requirements, and carry substantial liability insurance. Vendors submit bids or proposals with detailed product specifications, National Drug Codes, pricing by unit or by therapeutic category, and compliance documentation through electronic procurement portals.

Recent activity appears concentrated in the South and Upper Midwest, with solicitations from Seminole County, Florida (IFB60459723LAS, naloxone and drug deactivation systems, due July 26, 2023), the Texas Health and Human Services Commission (RFI HHS0017013 on direct-to-manufacturer prescription programs, response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions (S1070000015802, generic pharmaceuticals and OTC products, RFP due March 26, 2026). The MMCAP solicitation required products available by May 15, 2026, with contract awards effective July 1, 2026, and evaluated proposals on price competitiveness (75 percent weight), fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format compliance (5 percent). No explicit set-aside designations or disadvantaged-enterprise restrictions appear in the recent postings.